Search research articles
Contact Us
Filters
Showing results (61-70 of 69) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 69 results.
International Journal of Cancer
|
November 29, 2018
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
Yen-Ting Lin, Jin-Shing Chen, Wei-Yu Liao, et al.
Journal of Hepatology
|
January 22, 2009
The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma
Zhong-Zhe Lin, Hey-Chi Hsu, Chih-Hung Hsu, et al.
Leukemia & Lymphoma
|
October 23, 2002
Combination of 13-cis retinoic acid and interferon-alpha in the treatment of recurrent or refractory peripheral T-cell lymphoma
Chin-Lun Huang, Zhong-Zhe Lin, Ih-Jen Su, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 30, 2008
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy
Chih-Hsin Yang, Chong-Jen Yu, Jin-Yuan Shih, et al.
Therapeutic Advances in Medical Oncology
|
December 20, 2019
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
Shukui Qin, Stephen Lam Chan, Wattana Sukeepaisarnjaroen, et al.
Journal of Hepatocellular Carcinoma
|
August 2, 2021
An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma
Ying-Chun Shen, Pei-Chang Lee, Yu-Lun Kuo, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 22, 2008
High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy
Reury-Perng Perng, Chih-Hsin Yang, Yuh-Min Chen, et al.
Cancer Chemotherapy and Pharmacology
|
January 26, 2017
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
Ghassan K Abou-Alfa, Chia-Jui Yen, Chih-Hung Hsu, et al.
Cancer Discovery
|
October 3, 2019
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
Richard D Kim, Debashis Sarker, Tim Meyer, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 69) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 69 results.
International Journal of Cancer
|
November 29, 2018
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
Yen-Ting Lin, Jin-Shing Chen, Wei-Yu Liao, et al.
Journal of Hepatology
|
January 22, 2009
The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma
Zhong-Zhe Lin, Hey-Chi Hsu, Chih-Hung Hsu, et al.
Leukemia & Lymphoma
|
October 23, 2002
Combination of 13-cis retinoic acid and interferon-alpha in the treatment of recurrent or refractory peripheral T-cell lymphoma
Chin-Lun Huang, Zhong-Zhe Lin, Ih-Jen Su, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 30, 2008
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy
Chih-Hsin Yang, Chong-Jen Yu, Jin-Yuan Shih, et al.
Therapeutic Advances in Medical Oncology
|
December 20, 2019
A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma
Shukui Qin, Stephen Lam Chan, Wattana Sukeepaisarnjaroen, et al.
Journal of Hepatocellular Carcinoma
|
August 2, 2021
An Exploratory Study for the Association of Gut Microbiome with Efficacy of Immune Checkpoint Inhibitor in Patients with Hepatocellular Carcinoma
Ying-Chun Shen, Pei-Chang Lee, Yu-Lun Kuo, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 22, 2008
High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy
Reury-Perng Perng, Chih-Hsin Yang, Yuh-Min Chen, et al.
Cancer Chemotherapy and Pharmacology
|
January 26, 2017
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
Ghassan K Abou-Alfa, Chia-Jui Yen, Chih-Hung Hsu, et al.
Cancer Discovery
|
October 3, 2019
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
Richard D Kim, Debashis Sarker, Tim Meyer, et al.
Page
of 7